Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1195 - F-18 Flurodeoxyglucose Positron Emission Tomography (FDG PET) for the diagnosis of Alzheimer's Disease

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat at
Application Number1195
Application NameF-18 Fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer’s disease
Description of Medical ServiceFDG is a slightly radioactive form of glucose that can be safely injected into a patient. After 30 minutes a scan can then be performed with a PET camera, which takes approximately 15 minutes.
Description of Medical ConditionAlzheimer’s disease is the most common cause of dementia. It is progressive and leads to severe disability and then morbidity – on average seven years from diagnosis. Symptoms of Alzheimer’s disease are present for several years before diagnosis and the pathological process that leads to the dementia of Alzheimer’s disease begins a decade or more before diagnosis.
Consultation Protocol23 June 2014 - 18 July 2014
Consultation Protocol (PDF 338 KB)
Consultation Protocol (Word 103 KB)

Feedback and Survey
Application Feedback and Survey (PDF 44 KB)
Application Feedback and Survey (Word 91 KB)
Final ProtocolFinal Protocol (PDF 270 KB)
Final Protocol (Word 96 KB)
ReportsAssessment Report (PDF 896 KB)
Assessment Report (Word 838 KB)
MSAC OutcomesPublic Summary Document (PDF 205 KB)
Public Summary Document (Word 294 KB)

Meetings for this Application

Meeting Type:Date:
PASC16 to 17 April 2014
14 to 15 August 2014
ESC 12 to 13 February 2015
MSAC 1 to 2 April 2015

Page currency, Latest update: 06 July, 2015